Psychometric evaluation of the Subjective Well-being Under Neuroleptic Treatment Scale (SWN) in patients with schizophrenia, their relatives and controls

Psychiatry Research

Volumn 206, Issue 1, 2013, Pages 62-67

  Vothknecht, Sylke ^a,b   Meijer, Carin ^b   Zwinderman, Aeilko ^b   Kikkert, Martijn ^a   Dekker, Jack ^a   van Beveren, Nico ^c,d   Schoevers, Robert ^e   de Haan, Lieuwe ^b  

^a Arkin Mental Health Amsterdam   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d Delta Center for Mental Health Care   (Netherlands)

^e UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Heritability; Non affective psychosis; Psychosis continuum; Schizophrenia; Subjective experience; Subjective Well being Under Neuroleptic Treatment Scale (SWN)

Indexed keywords

ADULT; ARTICLE; CLINICAL EVALUATION; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE PREDISPOSITION; FEMALE; HERITABILITY; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; PATIENT ASSESSMENT; PRIORITY JOURNAL; PSYCHOLOGIC ASSESSMENT; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGICAL WELL BEING; PSYCHOMETRY; QUALITY OF LIFE; RATING SCALE; RELIABILITY; SCHIZOPHRENIA; SUBJECTIVE WELL BEING UNDER NEUROLEPTIC TREATMENT SCALE; WORLD HEALTH ORGANIZATION QUALITY OF LIFE;

ADULT; ANALYSIS OF VARIANCE; ANTIPSYCHOTIC AGENTS; COHORT STUDIES; FAMILY; FEMALE; HUMANS; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PSYCHIATRIC STATUS RATING SCALES; PSYCHOMETRICS; QUALITY OF LIFE; REPRODUCIBILITY OF RESULTS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84875394896     PISSN: 01651781     EISSN: 18727123     Source Type: Journal    
DOI: 10.1016/j.psychres.2012.09.004     Document Type: Article

References (50)

1. Balestrieri M., Giaroli G., Mazzi M., Bellantuono C. Performance of the italian version of the subjective well-being under neuroleptic (SWN) scale in schizophrenic outpatients. Pharmacopsychiatry 2006, 39:81-84.
2. Bartlett M.S. A note on the multiplying factors for various chi square approximations. Journal of the Royal Statistical Society 1954, 16:296-298.
3. Bartels M., Boomsma D.I. Born to be happy? The etiology of subjective well-being. Behavior Genetics 2009, 39(6):605-615.
4. Binbay T., Drukker M., Elbi H., Aksu Tamk F., Ökmay F., Onay H., Zagli N., Van Os J., Alptekin K. Testing the psychosis continuum: differential impact of genetic and nongenetic risk factors and comorbid psychopathology across the entire spectrum of psychosis. Schizophrenia Bulletin 2011, 38(5):992-1002.
5. Cervenka S., Petter Gustavsson J., Halldin C., Farde L. Association between striatal and extrastriatal dopamine D2-receptor binding and social desirability. Neuroimage 2010, 50:323-328.
6. Chen L., Phillips G., Johnston J., Kinon B.J., Ascher-Svanum H., Kollack-Walker S., Succop P., Naber D. The relationship, structure and profiles of schizophrenia measurements: a post-hoc analysis of the baseline measures from randomized clinical trial. BMC Psychiatry 2011, 11:203.
7. Couture S., Lecomte T., Leclerc C. Personality characteristics and attachment in first episode psychosis. Journal of Nervous and Mental Disease 2007, 195:631-639.
8. de Haan L., Lavalaye J., Linszen D.H., Dingemans P.M., Booij J. Subjective experience and striatal dopamine D(2) receptor occupancy in patients with schizophrenia stabilized by olanzapine or risperidone. American Journal of Psychiatry 2000, 157:1019-1020.
9. de Haan L., Weisfelt M., Dingemans P.M., Linszen D.H., Wouters L. Psychometric properties of the subjective well-being under neuroleptics scale and the subjective deficit syndrome scale. Psychopharmacology 2002, 162:24-28.
10. de Haan L., van Bruggen M., Lavalaye J., Booij J., Dingemans P.M., Linszen D.H. Subjective experience and D2 receptor occupancy in patients with recent-onset schizophrenia treated with low-dose olanzapine or haloperidol: a randomized, double-blind study. American Journal of Psychiatry 2003, 160:303-309.
11. de Haan L., van Nimwegen L., Amelsvoort T., Dingemans P., Linszen D.H. Improvement of subjective well-being and enduring symptomatic remission, a 5-year follow-up of first episode schizophrenia. Pharmacopsychiatry 2008, 41:125-128.
12. Dominguez M.D.G., Wichers M., Lieb R., Wittchen H.U., van Os J. Evidence that onset of clinical psychosis is an outcome of progressively more persistent subclinical psychotic experiences: an 8-year cohort study. Schizophrenia Bulletin 2011, 37:84-93.
13. Farde L., Gustavsson J.P., Jönsson E. D2 dopamine receptors and personality traits. Nature 1997, 385:590.
14. Hanssen M., Peeters F., Krabbendam L., Radstake S., Verdoux H., Van Os J. How psychotic are individuals with non-psychotic disorders?. Social Psychiatry and Psychiatric Epidemiology 2003, 38(3):149-154.
15. Hanssen M., Krabbendam L., Vollema M., Delespaul P., Van Os J. Evidence for instrument and family-specific variation of subclinical psychosis dimensions in the general population. Journal of Abnormal Psychology 2006, 115(1):5-14.
16. Hunter R., Barry S. Negative symptoms and psychosocial functioning in schizophrenia: neglected but important targets for treatment. European Psychiatry 2009, 27(6):432-436.
17. Johns J.C., van Os J. The continuity of psychotic experiences in the general population. Clinical Psychological Review 2001, 21:1125-1141.
18. 2 receptor gene variant and the personality trait detachment. Biological Psychiatry 2003, 53:577-584.
19. Kaiser H. An index of factorial simplicity. Psychometrika 1974, 39:31-36.
20. Karow A., Czekalla J., Dittmann R.W., Schacht A., Wagner T., Lambert M., Schimmelmann B.G., Naber D. Association of subjective well-being, symptoms, and side effects with adherence after 12 months of treatment in schizophrenia. Journal of Clinical Psychiatry 2007, 68:75-80.
21. Karow A., Naber D., Lambert M., Moritz S. Remission as perceived by people with schizophrenia, family members and psychiatrists. European Psychiatry 2009, 27(6):426-431.
22. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin 1987, 13(2):261-276.
23. Kinon B.J., Chen L., Ascher-Svanum H., Stauffer V.L., Kollack-Walker S., Zhou W., Kapur S., Kane J.M., Naber D. Challenging the assumption that improvement in functional outcomes is delayed relative to improvement in symptoms in the treatment of schizophrenia. Schizophrenia Research 2010, 118:176-182.
24. Kluge M., Wehmeier P.M., Dittmann R.W., Langer F., Czekalla J., Lehmann M., Kessler F.H., Beyenburg S., Naber D. A simple switching strategy for inadequately treated patients with schizophrenia to olanzapine: changes in psychopathology and subjective well-being. Pharmacopsychiatry 2005, 38:6-12.
25. Korver, N., Quee, P.J., Boos, H.B.M., Simons, C.J.P., 2011. Genetic Risk and Outcome of Psychosis (GROUP) investigators. Genetic Risk and Outcome of Psychosis (GROUP), a multi site longitudinal cohort study focused on gene-environment interaction: objectives, sample characteristics, recruitment and assessment methods. International Journal of Methods in Psychiatric Research 21, 205-221.
26. Lambert M., Naber D., Eich F.X., Schacht M., Linden M., Schimmelmann B.G. Remission of severely impaired subjective wellbeing in 727 patients with schizophrenia treated with amisulpride. Acta Psychiatrica Scandinavica 2007, 115:106-113.
27. Lambert M., Schimmelmann B.G., Naber D., Eich F.X., Schulz H., Huber C.G., Karow A. Early- and delayed antipsychotic response and prediction of outcome in 528 severely impaired patients with schizophrenia treated with amisulpride. Pharmacopsychiatry 2009, 42:277-283.
28. Linscott R.J., Van Os J. Systematic Reviews of categorical versus continuum models in psychosis: evidence for discontinuous subpopulations underlying a psychometric continuum. Implications for DSM-VDSM-VI, and DSM-VII. Annual Review of Clinical Psychology 2010, 6:391-419.
29. Maurino J., Cordero L., Ballesteros J. The subjective well-being under neuroleptic scale-short version (SWN-K) and the SF-36 health survey as quality of life measures in patients with schizophrenia. Patient Preference and Adherence 2012, 6:83-85.
30. Mizrahi R., Rusjan P., Agid O., Graff A., Mamo D.C., Zipursky R.B., Kapur S. Adverse subjective experience with antipsychotics and its relationship to striatal and extrastriatal D2 receptors: a PET study in schizophrenia. American Journal of Psychiatry 2007, 164:630-637.
31. 2 receptors in patients treated with dopamine partial agonist and full antagonist antipsychotics. International Journal of Neuropsychopharmacology 2009, 12:715-721.
32. Naber D., Walther A., Kircher T., Hayek D., Holzbach R. Subjective effects of neuroleptics predict adherence. Prediction of Neuroleptic Treatment Outcome in Schizophrenia: Concepts and Methods 1994, 85-98. Springer, Wien. W. Gaebel, A.G. Awad (Eds.).
33. Naber D. A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life, adherence and other clinical variables. International Clinical Psychopharmacology 1995, 10(Suppl. 3):133-138.
34. Naber D., Moritz S., Lambert M., Rajonk F., Holzbach R., Mass R., Andresen B., Frank P., Rüdiger H., Reinhard M., Burghard A. Improvement of schizophrenia patients' subjective well-being under atypical antipsychotic drugs. Schizophrenia Research 2001, 50:79-88.
35. Naber D., Riedel M., Klimke A., Vorbach E.U., Lambert M., Kühn K.U., Bender S., Bandelow B., Lemmer W., Moritz S., Dittmann R.W. Randomized double blind comparison of olanzapine vs. clozapine on subjective well-being and clinical outcome in patients with schizophrenia. Acta Psychiatrica Scandinavica 2005, 111:106-115.
36. Nes R.B., Roysamb E., Tambs K., Harris J.R., Reichborn-Kjennerud T. Subjective well-being: genetic and environmental contributions to stability and change. Psychological Medicine 2006, 36:1033-1042.
37. Phillips G., Chen L., Johnston J., Stauffer V., Kinon B., Ascher-Svanum H., Kollack- Walker S., Naber D. Factor analysis and item response theory analysis of the subjective wellbeing under neuroleptic treatment scale: suggestion for item reduction. International Journal of Neuropsychopharmacology 2010, 13(S1):234.
38. Schennach-Wolff R., Jäger M., Obermeier M., Schmauss M., Laux G., Pfeiffer H., Naber D., Schmidt L.G., Gaebel W., Klosterkötter J., Heuser I., Kühn K.U., Lemke M.R., Rüther E., Klingberg S., Gastpar M., Seemüller F., Möller H.J., Riedel M. Quality of life and subjective well-being in schizophrenia and schizophrenia spectrum disorders: valid predictors of symptomatic response and remission?. World Journal of Biological Psychiatry 2010, 11:729-738.
39. Siamouli M., Moutou K., Pantoula E., Magiria S., Chatzivasileiou I., Arapidis K., Chatzivasileiou A., Deres S., Fountoulakis K.N. Preliminary data concerning the reliability and psychometric properties of the Greek translation of the 20-item Subjective Well-being Under Neuroleptic Treatment Scale (SWN-20). Annals of General Psychiatry 2009, 8:3.
40. Sprangers M.A.G., Sloan J.A., Veenhoven R., Cleeland C.S., Halyard M.Y., Abertnethy A.P., Baas F., Barsevick A.M., Bartels M., Boomsma D.I., Chauhan C., Dueck A.C., Frost M.H., Hall P., Klepstad P., Martin N.G., Miaskowski C., Mosing M., Movsas B., van Noorden C.J.F., Patrick D.L., Pedersen N.L., Ropka M.E., Shi Q., Shinozaki G., Singh J.A., Yang P., Zwinderman A.H. The Establishment of the GENEQOL-Consortium to Investigate the Genetic Disposition of Patient-Reported Quality-of-Life Outcomes. Twin Research and Human Genetics 2009, 12:301-311.
41. Sprangers M.A.G., Bartels M., Veenhoven R., Baas F., Martin N.G., Mosing M., Movsas B., Ropka M.E., Shinozaki G., Swaab D., The GENEQOL Consortium Which patient will feel down, which will be happy? The need to study the genetic disposition of emotional states. Quality of Life Research 2010, 19:1429-1437.
42. The WHOQOL Group, 1998. Development of the World Health Organization. WHOQOL-BREF quality of life assessment. Psychological Medicine 28, 551-558.
43. Trompenaars F.J., Masthoff E.D., Van Heck G.L., Hodiamont P.P., De Vries J. Tent validity, construct validity, and reliability of the WHOQOL-Bref in a population of Dutch adult psychiatric outpatients. Quality of Life Research 2005, 14:151-160.
44. van Nimwegen L., de Haan L., van Beveren N., van der Helm M., van den Brink W., Linszen D.H. Effect of olanzapine and risperidone on subjective well-being and craving for cannabis in patients with schizophrenia or other related disorders: a double blind randomized trial. Canadian Journal of Psychiatry 2008, 53:400-405.
45. Van Os J., Linscott R.J., Myin-Germeys I., Delespaul P., Krabbendam L. A systematic review and meta-analysis of the psychosis continuum: evidence for a psychosis proneness-persistence-impairment model of psychotic disorder. Psychological Medicine 2009, 39:179-195.
46. Van Os J., Kenis G., Rutten B.P.F. The environment and schizophrenia. Nature 2010, 468:203-212.
47. Vothknecht S., Schoevers R.A., de Haan L. Subjective well-being in schizophrenia as measured with the Subjective Well-Being under Neuroleptic Treatment scale: a review. Australian and New Zealand Journal of Psychiatry 2011, 45:182-192.
48. Wolters H.A., Knegtering H., Wiersma D., van den Bosch R.J. Evaluation of the subjects' response to antipsychotics questionnaire. International Clinical Psychopharmacology 2006, 21:63-69.
49. Wolters H.A., Knegtering H., van den Bosch R.J., Wiersma D. Effects and side effects of antipsychotic treatment in schizophrenia: pros and cons of available self-rating scales. Schizophrenia Research 2009, 112:114-118.
50. Wolters, H.A., Knegtering, H., van den Bosch, R.J., Wiersma, D., 2009b. Quality of life in schizophrenia in relation to patients' response to antipsychotics. In: Wolters, H.A., Desired and Undesired Effects of Antipsychotic Treatment from a Patients' Perspective. Thesis, University of Groningen.